FDA Warning Letter Breakdown: Inside a GLP Collapse at a Chinese Testing Facility Data integrity problems reveal what happens when compliance becomes theater and why the firm voluntarily suspended all FDA-related non-clinical testing through December 2027
People with deficiencies have lower mineral density, making their bones more fragile and prone to breaking
The molecular biology, endocrinology, and physiology of the prostate and seminal vesicles
Evidence and Research Comparison# Mazdutide Research# Mazdutide was approved in China in June 2025 for weight management, making it the first GLP-1/glucagon dual agonist to receive regulatory approval anywhere: Phase 3 obesity (China) : Up to 20.1% body weight reduction at the 9 mg dose over 60 weeks
With compounders stepping in to meet that demand, the FDA is reasserting its requirements over a fiercely competitive market
Its manufactured through a unique fermentation process to ensure purity, stability, and bioavailability
